Welcome to our dedicated page for Mural Oncology PLC SEC filings (Ticker: MURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates historical U.S. Securities and Exchange Commission filings for Mural Oncology plc (formerly Nasdaq: MURA), an Irish public limited company that operated as a clinical-stage immuno-oncology biotechnology company. These filings document key corporate events, including its strategic review, financial reporting, and acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation.
Among the notable documents are multiple Forms 8-K reporting material events. An August 4, 2025 Form 8-K furnished a press release with financial results for the quarter ended June 30, 2025 and described the company’s decision to discontinue all clinical development of nemvaleukin alfa and explore strategic alternatives. An August 20, 2025 Form 8-K detailed the transaction agreement under which XRA 5 Corp. agreed to acquire the entire issued and to be issued share capital of Mural Oncology via an Irish High Court sanctioned scheme of arrangement, outlining the cash consideration structure and key closing conditions.
A later Form 8-K dated October 24, 2025 summarized the results of the scheme meeting and extraordinary general meeting at which Mural Oncology shareholders approved the scheme of arrangement and related resolutions. That filing also noted that, based on these approvals, completion of the acquisition was expected during the fourth quarter of 2025, subject to customary conditions and the High Court’s sanction of the scheme.
For investors and researchers reviewing MURA’s regulatory history, these filings provide insight into how the company communicated its strategic shift away from active research and development, its cost-conservation measures, and the legal and shareholder processes leading to its acquisition. In addition to 8-Ks, Mural Oncology’s annual and quarterly reports referenced in these documents contain further discussion of business risks, clinical programs, and cash resources during the period before the acquisition.
On this platform, SEC filings for Mural Oncology are supplemented with AI-powered summaries that highlight key terms from lengthy documents, explain the implications of material agreements such as the transaction agreement with XOMA Royalty, and clarify voting outcomes and conditions described in Forms 8-K. Real-time integration with the EDGAR system ensures that material event filings, annual reports (Form 10-K), quarterly reports (Form 10-Q), and other disclosures are captured as they become available. Users can also review insider and major shareholder information where reported in accordance with applicable rules, alongside explanatory notes derived from the underlying filings.
Trium Capital LLP filed an SEC Form 3 disclosing initial beneficial ownership in Mural Oncology plc (MURA US). The filing reports 1,760,097 shares of MURA held directly. The event date listed is 08/22/2025 and the form is signed by Fredrik Ostlund on 09/02/2025. The filing identifies the reporting person as a Director.
Mural Oncology plc disclosed a transaction agreement dated August 20, 2025, among Mural Oncology plc, XOMA Royalty Corporation and XRA 5 Corp. The filing describes mutual termination rights: the Company may terminate if the bidder breaches material covenants or if the Board approves a Superior Proposal before shareholder approval; the bidder may terminate for the Companys material breach, a Board change in recommendation, or if the Company solicits a Superior Proposal and does not cure within 15 days.
The filing also includes customary forward-looking disclaimers and lists related exhibits and communications, including a Rule 2.7 announcement, Rule 2.10 letters to shareholders and employees, a directors irrevocable undertaking, and the transaction agreement as exhibits. The disclosures focus on deal mechanics and termination conditions rather than financials.
Mural Oncology plc received a joint Schedule 13G/A from Armistice Capital, LLC and Steven Boyd reporting that the reporting persons do not beneficially own any ordinary shares of the issuer. The filing states zero shares owned and 0% of the class based on 17,324,359 shares outstanding as reported by the issuer.
The filing explains that Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice Capital exercises voting and investment power over the Master Fund's securities. The Master Fund disclaims beneficial ownership due to its inability to vote or dispose of the securities under the investment management agreement. The Master Fund retains the right to receive dividends or sale proceeds.
Mural Oncology plc received an amended Schedule 13G filing from Solas Capital Management, LLC and Frederick Tucker Golden reporting that neither the adviser nor Mr. Golden beneficially own any ordinary shares of the company. The filing lists the issuer's Dublin address and the security CUSIP G63365103. Both reporting parties state 0 shares owned and 0.0% of the class, and clarify the adviser relationship to private funds while noting the funds disclaim beneficial ownership. Signatures by Frederick Tucker Golden certify the accuracy of the statement.
FAQ
What is the current stock price of Mural Oncology PLC (MURA)?
What is the market cap of Mural Oncology PLC (MURA)?
